Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
Authors:
Open Access
- 8 February 2022
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (1) , e12657
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyLeukemia, 2013
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trialBlood, 2013
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia veraBlood, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia veraBlood, 2008
- Long‐term effects of the treatment of polycythemia vera with recombinant interferon‐αCancer, 2006
- Hydroxyurea Compared with Anagrelide in High-Risk Essential ThrombocythemiaNew England Journal of Medicine, 2005
- Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia VeraJournal of Clinical Oncology, 2005
- Anagrelide: A New Drug for Treating ThrombocytosisNew England Journal of Medicine, 1988
- Increased Incidence of Acute Leukemia in Polycythemia Vera Associated with Chlorambucil TherapyNew England Journal of Medicine, 1981